Eli Lilly’s weight loss drug slashes the risk of developing diabetes in long-term trial – CNBC

Eli Lilly’s weight loss drug slashes the risk of developing diabetes in long-term trial CNBCMounjaro/Zepbound Drastically Cuts Risk Of Type 2 Diabetes, Eli Lilly Report Suggests ForbesEli Lilly’s weight loss drug almost eliminates the risk of diabetes in overweight adults QuartzEli Lilly Says Weight-Loss Drug Sharply Reduces Diabetes Progression The Wall Street Journal